$33.34
-0.07-0.21%
Last update: Nov 11, 9:30 AM
Lakefront Biotherapeutics NV
LKFTNASDAQ
Lakefront Biotherapeutics rose 1.7% from $32.85 to $33.41, behind the S&P 500's +9.8%. Its worst day was Mar 24 (−6.6%), and its low came Aug 5 at $26.08.
Story events cover the past 12 months · Times ET
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Lakefront Biotherapeutics closed at its highest level of the year, 5.4% above where the year started.
+0.3% · S&P 500 +0.4%
EPS of $13.82 beat the $1.00 estimate on $1.0B revenue (est. $83.8M).
+1.4% · S&P 500 +0.7%
Lakefront Biotherapeutics shares fell 6.6%, while the S&P 500 fell 0.3%.
−6.6%, the year's worst day · S&P 500 −0.3%
EPS of $0.25 beat the $-1.27 estimate on $7.6M revenue (est. $16.0M).
−3.7% · S&P 500 −0.3%
EPS of $0.29 beat the $-13.52 estimate on $21.6M revenue (est. $7.2M).
+6.8%, the year's best day · S&P 500 −0.3%
Lakefront Biotherapeutics shares rose 4.9%, while the S&P 500 rose 0.2%.
+4.9% · S&P 500 +0.2%
Lakefront Biotherapeutics shares rose 5.0%, while the S&P 500 rose 0.9%.
+5.0% · S&P 500 +0.9%
Lakefront Biotherapeutics shares rose 6.0%, while the S&P 500 rose 1.7%.
+6.0% · S&P 500 +1.7%
Where it ended: a close of $33.41 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 11, 2026 (EPS est. $-0.19, revenue est. $8.7M).
Nothing in the past 12 months.
All LKFT dividend history
